Skip to main content
ANVS logo

Annovis Bio, Inc. (ANVS) Stock Price & Analysis

Annovis Bio, Inc. (ANVS) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.841 (+13.16%), as of the Nov 18, 2026 trading session; market cap $52.2M.

Educational signal · not a buy or sell recommendation · How to read this

$0.841 +$0.0978 (+13.16%) Market Cap $52.2M

Annovis Bio, Inc. · ANVS · NYSE

Annovis Bio, Inc. is a clinical-stage drug platform company focused on developing treatments for neurodegenerative diseases. Their lead compound, Buntanetap, targets Alzheimer's and Parkinson's diseases and is currently in clinical trials.

Price as of Nov 18, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Annovis Bio (ANVS)

Weak
Business Quality Average (57)
Financial Safety Fragile (10)
Valuation Bubble (2)
Growth Durability Shrinking (1)
Momentum Slipping (20)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.

Earnings yield is the main valuation drag relative to sector peers.

  • EPS beat 0 of the last 4 reports
  • Altman Z -0.84 · Piotroski F 0

Holding back: balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ANVS (57 recorded, newest six shown)
RecordedScoreBand
30Weak
27Weak
28Weak
28Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.841
Change on the day+13.16%
52-week range$0.6161 – $5.50
Market capitalisation$52.2M—
Price / earnings (trailing)-1.38
Shares traded on the day1.31M

Price & events

Other perspectives

Council score for Annovis Bio (ANVS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Negative
Growth Durability Negative
Momentum Weak

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
ROE Negative
Gross Margin Negative

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens disagrees with the Valuation pillar (Bubble, 2 of 100): it reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Annovis Bio (ANVS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Annovis Bio, Inc. (ANVS) is listed on NYSE. It employs 7 people and is led by Maria L. Maccecchini. The market values it at $52.2M.

2 · Latest results

What do the latest results show for Annovis Bio (ANVS)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Annovis Bio (ANVS)?

Short answer

What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -0.84 · Piotroski F 0. Trailing ratios: current ratio 3.47.

Data-derived red flags

  • Listing risk — at $0.841 the shares sit below the $1.00 minimum bid NYSE requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -0.84 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Annovis Bio (ANVS)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $10.95M · EPS -1.36 · 3 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for ANVS.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Annovis Bio compare with its peers?

Short answer

Annovis Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.13 Nov 19, 2026$481M60 5-pillar Nov 18, 2026
Annovis Bio (ANVS) — this page$0.841$52.2M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$10.95M
EPS estimate
$-1.36

Measured against a quoted price of $0.841 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ANVS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ANVS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Annovis Bio (ANVS)?

Read these with our analysis →

Common Questions About ANVS

These answers are editorial: 1 of these 9 answers is drawn from the ANVS research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ANVS?

ANVS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Annovis Bio, Inc. is a clinical-stage drug platform company focused on developing treatments for neurodegenerative diseases.

Is ANVS a good stock to buy?

Stock Expert AI does not rate ANVS buy, sell or hold. Annovis Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ANVS stock price today?

The last price recorded for Annovis Bio, Inc. (ANVS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about ANVS stock?

As a clinical-stage biotechnology company, Annovis Bio's stock performance is highly dependent on the success of its clinical trials. Analysts' opinions are likely to be divided, reflecting the inherent uncertainty of drug development.

What are the key factors to evaluate for ANVS?

Annovis Bio, Inc. (ANVS) holds a MoonshotScore in the low range. Annovis Bio is also exploring the potential of Buntanetap in treating Alzheimer's disease in individuals with Down Syndrome. Not financial advice.

How frequently does ANVS data refresh on this page?

ANVS's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ANVS's recent stock price performance?

Annovis Bio, Inc. (ANVS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates targeting the underlying mechanisms of neurodegenerative diseases. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ANVS overvalued or undervalued right now?

Annovis Bio, Inc. (ANVS) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ANVS?

Fractional-share availability for Annovis Bio, Inc. (ANVS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 6 from Financial Modeling Prep (FMP), 9 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.